ATE451928T1 - Verfahren zur behandlung von krankheiten mit pflanzenextrakten - Google Patents

Verfahren zur behandlung von krankheiten mit pflanzenextrakten

Info

Publication number: ATE451928T1
Authority: AT; Austria
Prior art keywords: extracts; methods; administered; diabetics; modulating
Prior art date: 2001-08-31

Application number

AT02770452T

Other languages

English (en)

Inventor

David Ribnicky

Ilya Raskin

Original Assignee

Univ Rutgers

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-31

Filing date

2002-08-30

Publication date

2010-01-15

2002-08-30 Application filed by Univ Rutgers filed Critical Univ Rutgers

2010-01-15 Application granted granted Critical

2010-01-15 Publication of ATE451928T1 publication Critical patent/ATE451928T1/de

Links

238000000034 method Methods 0.000 title abstract 5
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000000419 plant extract Substances 0.000 title 1
239000000284 extract Substances 0.000 abstract 5
241000196324 Embryophyta Species 0.000 abstract 2
230000002939 deleterious effect Effects 0.000 abstract 2
206010012601 diabetes mellitus Diseases 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
239000000463 material Substances 0.000 abstract 2
240000006891 Artemisia vulgaris Species 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
230000009286 beneficial effect Effects 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000012530 fluid Substances 0.000 abstract 1
238000005194 fractionation Methods 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
230000002352 nonmutagenic effect Effects 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
229930029653 phosphoenolpyruvate Natural products 0.000 abstract 1
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Natural Medicines & Medicinal Plants (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Neurology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Alternative & Traditional Medicine (AREA)
Botany (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Mycology (AREA)
Biotechnology (AREA)
Medical Informatics (AREA)
Microbiology (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Child & Adolescent Psychology (AREA)

AT02770452T 2001-08-31 2002-08-30 Verfahren zur behandlung von krankheiten mit pflanzenextrakten ATE451928T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31676001P	2001-08-31	2001-08-31
PCT/US2002/027892 WO2003020026A1 (en)	2001-08-31	2002-08-30	Methods for treating disorders using plant extracts

Publications (1)

Publication Number	Publication Date
ATE451928T1 true ATE451928T1 (de)	2010-01-15

Family

ID=23230559

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02770452T ATE451928T1 (de)	2001-08-31	2002-08-30	Verfahren zur behandlung von krankheiten mit pflanzenextrakten

Country Status (8)

Country	Link
US (2)	US6893627B2 (de)
EP (1)	EP1429602B1 (de)
JP (2)	JP4744081B2 (de)
AT (1)	ATE451928T1 (de)
AU (1)	AU2002335689B2 (de)
CA (1)	CA2459045A1 (de)
DE (1)	DE60234780D1 (de)
WO (1)	WO2003020026A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010041187A1 (en) *	1998-10-20	2001-11-15	Carl W Hastings	Performance-enhancing dietary supplement
US8703212B2 (en) *	1999-09-03	2014-04-22	Viraj Shah, Varion Limited	Base material for pharmaceutical and/or cosmetic cream (herbal composition for itchy or infected skin)
US7713546B1 (en) *	2001-04-03	2010-05-11	Soft Gel Technologies, Inc.	Corosolic acid formulation and its application for weight-loss management and blood sugar balance
KR100645385B1 (ko) *	2005-10-05	2006-11-23	주식회사 안지오랩	비만 억제용 조성물
US7232828B2 (en) *	2002-08-10	2007-06-19	Bethesda Pharmaceuticals, Inc.	PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
ATE397453T1 (de) *	2003-06-30	2008-06-15	Nestec Sa	Zusammensetzung zur behandlung und/oder vorbeugung von insulinresistenz
CA2580733A1 (en) *	2003-09-20	2005-04-07	Glykon Technologies Group, Llc	(-)-hydroxycitric acid for delaying gastric emptying
EP1708571A4 (de) *	2004-01-16	2009-07-08	Merck & Co Inc	Neue kristalline salze eines dipeptidylpeptidase-iv-hemmers
DE102004036047A1 (de) *	2004-07-24	2006-02-23	Bioghurt Biogarde Gmbh & Co. Kg	Physiologisch aktive Zusammensetzung
US20060051435A1 (en) *	2004-08-19	2006-03-09	Udell Ronald G	Nutritional supplement for body fat reduction
US20100087546A1 (en) *	2005-04-20	2010-04-08	Biogenic Innovations, Llc	Use of dimethyl sulfone (msm) to reduce homocysteine levels
US12059446B1 (en) *	2005-05-20	2024-08-13	4Life Patents, Llc	Compositions and methods for supporting metabolic and endocrine system function
WO2007004883A2 (en) *	2005-07-05	2007-01-11	N.V. Nutricia	A carbohydrate fraction and use thereof for a flat postprandial glucose response
AU2006291134C1 (en)	2005-09-12	2013-08-15	Abela Pharmaceuticals, Inc.	Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
US8480797B2 (en)	2005-09-12	2013-07-09	Abela Pharmaceuticals, Inc.	Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
US9427419B2 (en)	2005-09-12	2016-08-30	Abela Pharmaceuticals, Inc.	Compositions comprising dimethyl sulfoxide (DMSO)
WO2007033180A1 (en)	2005-09-12	2007-03-22	Abela Pharmaceuticals, Inc.	Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
WO2007043306A1 (ja)	2005-09-30	2007-04-19	Morinaga Milk Industry Co., Ltd.	インスリン抵抗性改善剤
AU2006300640C1 (en) *	2005-09-30	2010-04-08	Morinaga Milk Industry Co., Ltd.	Agent for improving insulin resistance
US7858599B2 (en)	2005-12-30	2010-12-28	Hander Robert W	Enhancement of urogenital function
US20070224301A1 (en) *	2006-03-21	2007-09-27	Ribnicky David M	Compounds from an extract of Artemisia and methods for treating disorders
US20070264360A1 (en) *	2006-05-12	2007-11-15	Feldman Spencer B	Gall bladder and liver cleansing suppository
MX2008014784A (es)	2006-05-19	2009-01-30	Mary Kay Inc	Compuestos de glicerilo y acido glicolico.
US20090061031A1 (en) *	2006-07-07	2009-03-05	Sylvia Lee-Huang	Compositions and methods for treating obesity, obesity related disorders and for inhibiting the infectivity of human immunodeficiency virus
CN101517086A (zh)	2006-07-21	2009-08-26	希乐克公司	生物质转化系统
PL2068901T3 (pl) *	2006-10-05	2019-05-31	Dsm Ip Assets Bv	Zastosowanie hydroksytyrozolu do zmniejszenia ilości kwasu mlekowego w osoczu
CN101102783B (zh) *	2006-12-13	2010-11-17	北京绿色金可生物技术股份有限公司	黑大豆皮提取物及其提取方法和应用
IL181404A0 (en) *	2007-02-18	2007-07-04	R A M Biotechnological Res Ltd	Herbal compositions comprising plant material of artemisia herba-alba (asso) asteraceae and/or extracts thereof
US8187643B2 (en) *	2007-03-28	2012-05-29	Greg Steininger, legal representative	Shampoo formulation for treatment of hair loss and method of use
US20080311230A1 (en) *	2007-06-17	2008-12-18	Omer Harun A	Preparation of Artemisia to treat human cancer, autoimmune disease, IgA-Nephropathy, and to counteract weight loss in cancer patients
IL184312A0 (en) *	2007-06-28	2008-01-20	Ascarit Ltd	Herbal compositions for the treatment of diabetes and/or conditions associated therewith
US20090263505A1 (en) *	2008-04-21	2009-10-22	George Roderick Hammons	Dietary therapeutic compositions for ameliorating disease symptoms and conditions associated with diabetes
EP2130443A1 (de) *	2008-06-06	2009-12-09	Finzelberg GmbH & Co. KG	Wasserlösliche Extrakte von Artemisia dracunculus (Tarragon) zur Verbesserung des Glukosestoffwechsels
WO2009147229A1 (en) *	2008-06-06	2009-12-10	Phytolab Gmbh & Co. Kg	Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon
BRPI0921494A2 (pt)	2008-11-03	2018-10-30	Prad Reasearch And Development Ltd	método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
US9901551B2 (en)	2009-04-20	2018-02-27	Ambra Bioscience Llc	Chemosensory receptor ligand-based therapies
US8828953B2 (en) *	2009-04-20	2014-09-09	NaZura BioHealth, Inc.	Chemosensory receptor ligand-based therapies
CN101548982B (zh) *	2009-05-12	2012-02-01	中国人民解放军第二军医大学	一种二氢黄酮类化合物在制备防治糖尿病药物中的应用
US9855212B2 (en)	2009-10-30	2018-01-02	Abela Pharmaceuticals, Inc.	Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases
ES2608483T3 (es) *	2009-12-18	2017-04-11	Metabolic Technologies, Inc.	Método mejorado de administración de beta-hidroxi-beta-metilbutirato (HMB)
BR112013009635A2 (pt)	2010-10-19	2016-07-12	Elcelyx Therapeutics Inc	terapias à base de ligante de receptor quimiossensorial
US20120178813A1 (en)	2011-01-12	2012-07-12	Thetis Pharmaceuticals Llc	Lipid-lowering antidiabetic agent
US9382187B2 (en)	2012-07-10	2016-07-05	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
US8765811B2 (en)	2012-07-10	2014-07-01	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
TWI495464B (zh) *	2013-02-08	2015-08-11	Univ Nat Taiwan	苦味化合物於活化ｇｌｐ－１分泌之用途
SG10201707324WA (en) *	2013-03-12	2017-10-30	Hmi Inc	Plant extracts with anti-diabetic and other useful activities
KR102158895B1 (ko)	2013-03-12	2020-09-22	마리 케이 인코포레이티드	보존 시스템
WO2015171516A1 (en)	2014-05-05	2015-11-12	Thetis Pharmaceuticals Llc	Compositions and methods relating to ionic salts of peptides
US9242008B2 (en)	2014-06-18	2016-01-26	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of fatty acids
CN107074884A (zh)	2014-06-18	2017-08-18	西蒂斯制药有限责任公司	活性剂的矿物质氨基酸复合物
JP6985139B2 (ja) *	2014-10-21	2021-12-22	アルピニア・ローダナム・インスティテュート・オブ・フィトファーマシューティカル・サイエンシーズ・アクチェンゲゼルシャフトAlpinia Laudanum Institute Of Phytopharmaceutical Sciences Ag	ボスウェリア属の植物に由来する抽出物、並びに関連する生成物及び使用
KR102437682B1 (ko)	2016-06-03	2022-08-29	테티스 파마수티컬스 엘엘씨	특화된 사전 해소 매개체의 염에 관한 조성물 및 방법
KR20200016252A (ko) *	2017-05-12	2020-02-14	하우지 파마슈티컬 리서치 래보러토리즈, 엘.엘.씨.	항-당뇨병성 및 다른 유용한 활성을 갖는 식물 추출물
CN112336847B (zh) *	2021-01-11	2021-07-13	中城环建科技股份有限公司	益生菌组合物在制备药物中的用途
CN112931120B (zh) *	2021-01-29	2023-01-24	中国科学院地理科学与资源研究所	一种在盐碱地种植胡芦巴的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4534317A (en) *	1984-08-30	1985-08-13	Cape Cod Research	Procedures for monitoring fish food consumption
JPH0356585A (ja) *	1989-07-26	1991-03-12	Shokuhin Sangyo Hai Separeeshiyon Syst Gijutsu Kenkyu Kumiai	抗酸化剤
JP3536111B2 (ja) *	1992-06-29	2004-06-07	株式会社ナリス化粧品	ムコ多糖類断片化抑制剤および化粧料
GB9606579D0 (en) *	1996-03-28	1996-06-05	Phytotech Ltd	Pharmaceutical composition and methods for the manufacture thereof
JPH1036282A (ja) *	1996-07-18	1998-02-10	Pola Chem Ind Inc	ムコ多糖類切断抑制剤
JPH1036280A (ja) *	1996-07-18	1998-02-10	Pola Chem Ind Inc	ヒドロキシラジカル消去剤
JPH1077211A (ja) *	1996-09-05	1998-03-24	Pola Chem Ind Inc	メークアップ化粧料
JP4127875B2 (ja) *	1997-06-11	2008-07-30	株式会社ロッテ	抗ヘリコバクター・ピロリ剤
JP3978517B2 (ja) *	1997-07-25	2007-09-19	株式会社ロッテ	抗レジオネラ属菌組成物
JPH11318445A (ja) *	1998-05-14	1999-11-24	Aomori Prefecture	ノイラミニダーゼ阻害物質製造法
KR20000019716A (ko)	1998-09-15	2000-04-15	박호군	바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
SE9903407L (sv)	1998-09-26	2000-03-27	Kijang Medical Co	Metod för framställning av farmaceutiska artemisia-extrakt samt apparat för elektrisk moxabränning med användande av extraktet

2002
- 2002-08-30 JP JP2003524349A patent/JP4744081B2/ja not_active Expired - Fee Related
- 2002-08-30 EP EP02770452A patent/EP1429602B1/de not_active Expired - Lifetime
- 2002-08-30 AU AU2002335689A patent/AU2002335689B2/en not_active Ceased
- 2002-08-30 AT AT02770452T patent/ATE451928T1/de not_active IP Right Cessation
- 2002-08-30 US US10/232,756 patent/US6893627B2/en not_active Expired - Lifetime
- 2002-08-30 CA CA002459045A patent/CA2459045A1/en not_active Abandoned
- 2002-08-30 WO PCT/US2002/027892 patent/WO2003020026A1/en not_active Ceased
- 2002-08-30 DE DE60234780T patent/DE60234780D1/de not_active Expired - Lifetime
2004
- 2004-08-10 US US10/914,987 patent/US20050069598A1/en not_active Abandoned
2009
- 2009-10-27 JP JP2009247134A patent/JP2010018637A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
WO2003020026A1 (en)	2003-03-13
CA2459045A1 (en)	2003-03-13
US20030072822A1 (en)	2003-04-17
JP4744081B2 (ja)	2011-08-10
EP1429602A1 (de)	2004-06-23
US20050069598A1 (en)	2005-03-31
EP1429602B1 (de)	2009-12-16
EP1429602A4 (de)	2005-12-21
DE60234780D1 (de)	2010-01-28
JP2005505544A (ja)	2005-02-24
AU2002335689B2 (en)	2008-08-07
JP2010018637A (ja)	2010-01-28
US6893627B2 (en)	2005-05-17

Legal Events

Date	Code	Title	Description
2010-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60234780D1 (de)	2010-01-28	Verfahren zur behandlung von krankheiten mit pflanzenextrakten
DE602005020269D1 (de)	2010-05-12	Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
DE60223058D1 (de)	2007-11-29	Zusammensetzungen und verfahren zur behandlung von diabetes
DE602004012745D1 (de)	2008-05-08	Synergistische zusammensetzung zur behandlung von diabetes mellitus
DE602004031134D1 (de)	2011-03-03	Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE191513T1 (de)	2000-04-15	Verfahren zur amplifikation von nukleinsäuren
ATE395052T1 (de)	2008-05-15	Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
DE60143850D1 (de)	2011-02-24	Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen
DE69535264D1 (de)	2006-11-23	Verfahren zur behandlung von diabetes mittels kgf
ATE348808T1 (de)	2007-01-15	Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
DE69228949D1 (de)	1999-05-20	Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
DK0769915T3 (da)	2001-12-27	Anvendelse af en fraktion indeholdende organiske syrer og fraktion indeholdende syre
DE60233433D1 (de)	2009-10-01	PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
PT87523A (pt)	1989-05-31	Mischkristalle aus insulin und insulinderivaten verfahren zur herstellung dieser mischkristalle diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
ATE78397T1 (de)	1992-08-15	Verwendung von p-chlorophenoxyazetat von n,ndimethylbiguanidzur behandlung von neuropathien und nervendegeneration.
DE60316443D1 (de)	2007-10-31	Zusammensetzung zur köderung von blutsaugenden arthropoden und fruchtfliegen
DE69523605D1 (de)	2001-12-06	Verfahren zur herstellung vom aktieven protein dimerischen
FR2866890B1 (fr)	2008-04-04	Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
ATE428730T1 (de)	2009-05-15	Verfahren zur herstellung einer alpha-1- antitrypsinlösung
ATE281841T1 (de)	2004-11-15	Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE413867T1 (de)	2008-11-15	Methode zur behandlung von bewegungsstörungen mit barbitursäure derivaten.
DE59206036D1 (de)	1996-05-23	Piperidylmethyl substituierte Chromanderivate als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems
ATE209914T1 (de)	2001-12-15	Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
ATE66340T1 (de)	1991-09-15	Verfahren zur foerderung von wachstum und gesundheit von nutzpflanzen.
DE69914825D1 (de)	2004-03-25	Behandlung von Triebspitzen (Haupttriebe) von Bäumen aus den Familien Picea und Abies